SenseTime, founded by Chinese University of Hong Kong professor Tang Xiaoou, has begun exploring an initial public offering as early as 2018.

The monoclonal antibody developer, which counts EMBL Ventures and GV among its investors, had initially raised $40m when it floated last week.

The EMBL Ventures-backed immunotherapy developer floated in an underpriced offering and received $20m in a private placement from NEA.

Pennsylvania spinout Apellis Pharmaceuticals has floated on the Nasdaq Global Select Market after raising $150m in its initial public offering.

EMBL-backed Arsanis hopes to sell 3,125,000 shares priced at $15 to $17 and raise a total of up to $61m in its initial public offering.

The bacterial infections drug developer, based on research at Harvard Medical School, has gone public.

Spero Therapeutics, a bacterial infection treatment developer based on research at Harvard Medical School, has filed to raise up to $86.3m in an initial public offering.

Nucana, a Scottish Investment Bank-backed cancer treatment developer, and Nightstar Therapeutics, an Oxford spinout focused on retinal gene therapies, have entered the public market.

The University of Oxford spinout has filed for an $86.25m initial public offering in the US just three years after being founded.

The oncology drug developer has raised $92.5m in VC funding, $11.5m of which came from MedImmune Ventures, the CVC unit that now owns a 16.7% stake.